The short version of thymalfasin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-29 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
== Personal life == Flay married Debra Ponzek, also a chef, on May 11, 1991. Flay and Ponzek divorced in 1993, and Flay married his second wife, Kate Connelly, in 1995. They have a daughter, Sophie Flay. Flay and Connelly separated in 1998 and later divorced. Flay married actress Stephanie March on February 20, 2005. March and Flay divorced in July 2015. Flay dated Heléne Yorke from February 2016 to early 2019. In November 2021, Flay went public with girlfriend Christina Perez after about a year of dating. The couple broke up in 2024. As of March 2025, Flay is in a relationship with fellow chef Brooke Williamson. Flay is a self-proclaimed 'cat person' and has lived with cats most of his life. He has had three Maine Coons: Nacho, an orange tabby Maine Coon; Stella, a brown tabby Maine Coon five years younger than Nacho; and Canelo. In October 2023, Flay announced that Nacho had died. Flay has an interest in thoroughbred horse racing, and is the owner of graded stakes race winners:
Eli Lilly pleaded guilty to a US federal criminal misdemeanor charge of illegally marketing Zyprexa, actively promoting the drug for off-label uses, particularly for the treatment of dementia in the elderly. The $1.415 billion penalty included an $800 million civil settlement, a $515 million criminal fine, and forfeit assets of $100 million. The US Justice Department said the criminal fine of $515 million was the largest ever in a healthcare case and the largest criminal fine for an individual corporation ever imposed in a US criminal prosecution of any kind. "That was a blemish for us," John C. Lechleiter, CEO of Lilly, said. "We don't ever want that to happen again. We put measures in place to assure that not only do we have the right intentions in integrity and compliance, but we have systems in place to support that." In an internal email, Lechleiter had stated "we must seize the opportunity to expand our work with Zyprexa in this same child-adolescent population" for off-label use. In January 2020, lawyer James Gottstein published a book titled The Zyprexa Papers, summarizing the legal activities surrounding Zyprexa and their impact on the political landscape of psychiatry and antipsychiatry in the US. The book details how he obtained the Zyprexa papers, including how Will Hall and a small group of "psychiatric survivors" spread the Zyprexa Papers on the Internet, and Gottstein's battles on behalf of Bill Bigley, the psychiatric patient whose ordeal made possible the exposure of the Zyprexa Papers.
On 9 July, Thom took Florey and Heatley to Washington, D.C., to meet Percy Wells, the acting assistant chief of the USDA Bureau of Agricultural and Industrial Chemistry and as such the head of the USDA's four laboratories. Wells sent an introductory telegram to Orville May, the director of the UDSA's Northern Regional Research Laboratory (NRRL) in Peoria, Illinois. They met with May on 14 July, and he arranged for them to meet Robert D. Coghill, the chief of the NRRL's fermentation division, who raised the possibility that fermentation in large vessels might be the key to large-scale production. On 17 August, Florey met with Alfred Newton Richards, the chairman of the Committee for Medical Research (CMR) of the Office of Scientific Research and Development (OSRD), who promised his support. On 8 October, Richards held a meeting with representatives of four major pharmaceutical companies: Squibb, Merck, Pfizer and Lederle. Vannevar Bush, the director of OSRD was present, as was Thom, who represented the NRRL. Richards told them that antitrust laws would be suspended, allowing them to share information about penicillin. This was not legalized until 7 December 1943, and it covered only penicillin and no other drug. OSRD arranged with the War Production Board (WPB) for them to have priority for equipment for laboratories and pilot plants.
Lowering transaction costs in commercial markets: Digital payments, whether integrated in e-commerce platforms or in mobile money accounts, e-wallets, etc., reduce transactions costs within agricultural markets. The need for safe, rapid monetary transactions is particularly apparent in rural areas. Plus, digital payments can provide a gateway to bank accounts, insurance, and credit. Using distributed ledger technologies or smart contracts is another way to reduce trust-related transaction costs in commercial markets. Many retail and food companies have partnered with IBM to develop blockchain pilots related to food safety and traceability, and Alibaba is testing blockchain to reduce fraud in agri-food e-commerce between China and Australia/New Zealand. Lowering transaction costs in government services: Digital payments can also streamline government delivery of agricultural subsidies. In 2011, the Nigerian Federal Ministry of Agriculture and Rural Development started delivering fertilizer subsidy vouchers to e-wallets on mobile phones; by 2013, they had reached 4.3 million smallholders nationwide. Compared to the previous program, the e-vouchers cut costs: from 2011 to 2013, the cost per smallholder farmer receiving fertilizer went from US$225–300 to US$22. The e-vouchers also reached more smallholders, increasing from between 600,000-800,000 in 2011 to 4.3 million in 2013.
This approach falls below international standards, where adverse action is a purely objective test. By contrast in CFMEU v Clermont Coal Pty Ltd an employer was found liable for selecting a union organiser named Mr Scott for redundancy, ostensibly on the basis of "attitude", but where all supervisor's assessments of "attitude" came from Scott's role in union organising, and Scott had an objectively better work record than others scored higher.
Sources: en.wikipedia.org
Dual Wield System New Weapons Weapon Models update Several new gamemodes After achieving enough votes to pass Steam Greenlight in October of 2013, Fistful of Frags released as a standalone title on Steam on May 9th, 2014. Due to complications with remaking the mod in Source SDK 2013, several gamemodes were cut. With the remaining gamemodes being deathmatch and team deathmatch. On February 6th, 2015, Fistful of Frags reached 1,000,000 Installations. From 2014 to 2025, updates for the game usually included further polishing, tweaked gameplay balancing, new map additions and 3 Halloween updates.
These include radionuclides occurring in the decay chains of primordial uranium and thorium (radiogenic nuclides), such as radon-222. Others are the products of interactions with energetic cosmic rays (the cosmogenic nuclides), such as carbon-14. This gives a total of about 350 naturally occurring nuclides, some of which are difficult to detect. Other nuclides may be occasionally produced naturally by rare cosmogenic interactions or as a result of other natural nuclear reactions (nucleogenic nuclides), and these are generally even less detectable. Non-primordial nuclides may also be detected in the spectra of stars; technetium is well established, and others have been claimed. The remaining nuclides are known solely from artificial nuclear transmutations. Some, such as caesium-137 and krypton-85, are detected in the environment, but only (or practically only) from deliberate or accidental release of artificial production, as fission products (from nuclear weapons or nuclear reactors), for industrial or medical uses, or otherwise.
The pharynx is a part of the conducting zone of the respiratory system and also a part of the digestive system. It is the part of the throat immediately behind the nasal cavity at the back of the mouth and above the esophagus and larynx. The pharynx is made up of three parts. The lower two parts—the oropharynx and the laryngopharynx are involved in the digestive system. The laryngopharynx connects to the esophagus and it serves as a passageway for both air and food. Air enters the larynx anteriorly but anything swallowed has priority and the passage of air is temporarily blocked. The pharynx is innervated by the pharyngeal plexus of the vagus nerve. Muscles in the pharynx push the food into the esophagus. The pharynx joins the esophagus at the oesophageal inlet which is located behind the cricoid cartilage.
== Classical era == Because silver was extensively used as a decorative material and an exchange medium, lead deposits came to be worked in Asia Minor from 3000 BC; later, lead deposits were developed in the Aegean and Laurion. These three regions collectively dominated production of mined lead until c. 1200 BC. Beginning c. 2000 BC, the Phoenicians worked deposits in the Iberian peninsula; by 1600 BC, lead mining existed in Cyprus, Greece, and Sardinia. Rome's territorial expansion in Europe and across the Mediterranean, and its development of mining, led to it becoming the greatest producer of lead during the classical era, with an estimated annual output peaking at 80,000 tonnes. Like their predecessors, the Romans obtained lead mostly as a by-product of silver smelting. Lead mining occurred in central Europe, Britain, Balkans, Greece, Anatolia, Hispania, the latter accounting for 40% of world production.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.